Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.96) per share. This is a 62.71 percent decrease over losses of $(0.59) per share from the same period last year.
Raymond James Maintains Outperform on Meta Platforms, Raises Price Target to $238
Raymond James analyst Aaron Kessler maintains Meta Platforms (NASDAQ:META) with a Outperform and raises the price target from $220 to $238.
